Schistosomiasis is one of the major communicable diseases of public health importance in the developing world. The World Health Organization estimates that 600 million people are at risk for infection, that 200 million are infected, and that 20 million of those who are infected will develop a severe illness. It has also been estimated that 20,000 deaths are associated with the disease annually [1] . Schistosoma haematobium mainly affects the urinary system, although infection of the genital organs is not infrequent among individuals in areas of endemicity [2] [3] [4] [5] [6] . The consequences of genital involvement, in terms of morbidity and fertility, are unclear. There is renewed interest in hematospermia as a presenting symptom of schistosomiasis in travelers returning from areas of endemicity [7, 8] . Schistosomal eggs have been found in both the prostate and the seminal vesicles of affected persons [5] . Praziquantel is the drug of choice for the treatment of most cases of schistosomiasis. However, the prostate is known to be "hostile" to many antimicrobials pharmacologically. Whether the levels of praziquantel attained in the prostate are adequate for the killing of parasites is unclear. The purpose of this report is to describe the clinical course of schistosomal hematospermia in (nonimmune) travelers and to identify the diagnostic and therapeutic challenges associated with the condition.
Patients and methods.
We conducted a retrospective analysis of travelers returning to Israel who complained of hematospermia that was eventually found to have been caused by schistosomal infection. Three travel clinics, located in Tel Aviv, Haifa, and Jerusalem, Israel, were contacted and asked to provide data on returning travelers with hematospermia. Diagnosis of schistosomal hematospermia was based on the presence of schistosomal eggs either in a direct smear of seminal fluid or in a prostate biopsy specimen. Urinalysis was routinely performed for all patients, and, in addition, a 24-h urine collection was concentrated to increase the likelihood of detection of schistosomal eggs. Serological testing for Schistosoma species (by Falcon assay screening test [FAST]-ELISA) and species identification (by immunoblot assay) were performed at the Laboratory for Parasitic Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. Treatment involved the use of praziquantel (Biltricide; Bayer AG).
Results. From 1997 through 1999, 70 patients with schistosomal infection were treated at the 3 aforementioned travel clinics. Four (5.7%) of these 70 patients had hematospermia. All 4 patients were travelers who were returning to Israel from Africa and who had contracted disease in Lake Malawi in Africa. Their mean age was 24.3 years (table 1), which parallels the age of the average Israeli backpacker. Onset of symptoms of hematospermia occurred 3-8 months after exposure. Two patients complained of having lower abdominal pain after ejaculation, and 1 patient had testicular hyperesthesia. In 2 patients (patients 1 and 2), gross hematuria developed before hematospermia; however, at the time of presentation, all 4 patients had negative results of urinalysis, and S. haematobium eggs were found in semen specimens from patients 1, 3, and 4 ( figure 1 ). In addition, schistosomal eggs were found in a prostate biopsy specimen from patient 2 (figure 2). Considerable eosinophilia was found only in patient 1. Findings of ultrasonography of the prostate were normal, except for patient 2, who had slight enlargement of the prostate (table 1) .
Patients 1-3 received the recommended treatment for urinary schistosomiasis, which included praziquantel, 40 mg/kg given in 2 divided doses in a single day. However, all 3 patients experienced recurrence of hematospermia with associated pain and discomfort in the genital area (table 2) . A second examination of semen specimens revealed the presence of schistosomal eggs. (A viability test was not performed.) Patient 4, who received an initial dose of praziquantel (60 mg/kg) that was higher than the dose given to the other 3 patients, did not experience recurrence of infection. At follow-up, which was done 1-3 years after the last course of treatment was completed, all patients were asymptomatic. Case report. A 24-year-old male traveler with hematuria was first seen in January 1998. His medical history revealed no chronic illnesses. He had visited Tanzania, Kenya, and, finally, Lake Malawi, where he had stayed for 1 month while taking a diving course. Four months after he was exposed to S. haematobium infection in Lake Malawi, he noticed macroscopic hematuria (without having a history of Katayama fever after exposure). S. haematobium eggs were found in a urine sample. The patient was treated with praziquantel, 40 mg/kg given in 2 divided doses in a single day, and the hematuria disappeared. Three months later, he started complaining of paresthesias in both testicles; soon afterward, hematospermia was noted.
The findings of physical examination were unremarkable. Results of blood tests were within normal limits and did not demonstrate eosinophilia (absolute eosinophil count, 90 eosinophils/mm 3 ). The findings of urinalysis were normal, but analysis of a 5-h urine collection revealed S. haematobium eggs. The results of serological testing for Schistosoma species (by FAST-ELISA), performed at the CDC, were positive. Therefore, praziquantel, 40 mg/kg administered in 2 divided doses in a single day, was given again. The hematospermia cleared but then recurred 2 months after the second treatment with praziquantel was received.
The patient was seen at a urologic clinic, where an enlarged and slightly tender prostate was identified. Transrectal ultrasonography indeed showed an enlarged prostate, and biopsy revealed the presence of S. haematobium eggs ( figure 2) .
Finally, an increased dose of praziquantel, 60 mg/kg, was given together with prednisone, 40 mg/day for 10 days (as an anti-inflammatory agent). Alleviation of the patient's symptoms occurred within a short time, and, at follow-up, the size of his prostate had returned to normal. At follow-up 2 years later, the patient was found to be still asymptomatic (tables 1 and 2, patient 2).
Discussion Recent evidence from a field study indicates that the incidence of genital involvement in men with schistosomal infection is higher than previously was appreciated [4] . However, this presentation seems to be rare among travelers, with only 2 previous reports appearing in the literature [7, 8] . The recent increase in the flow of travelers to areas of endemicity should increase the number of cases of schistosomal infection seen by physicians in developed countries [9] . Thus, the clinical spectrum of the disease should be known to the medical community.
In all 4 travelers described in the present report, hematospermia presented without associated hematuria; this made the diagnosis more challenging, although hematuria had occurred several months previously in 2 of the patients. In addition, the long interval between the apparent exposure and presentation, as well as the lack of eosinophilia, added to the difficulty in reaching the correct diagnosis. This diagnostic challenge indicates that obtaining a travel history is mandatory when evaluating a patient. Exposure to freshwater in Africa should be the leading clue toward making a diagnosis. All of our patients were infected in Lake Malawi, which is a popular tourist destination and which recently was found to be severely infected mainly with S. haematobium [10] . All of our patients had S. haematobium infection, which is the main source of genital involvement. It is remarkable, however, that Schistosoma mansoni, which usually resides in the mesenteric vessels, has also been reported as a cause of hematospermia [7, 11] For 1 of our patients, rectal examination revealed a mildly enlarged and tender prostate, but the prostates of the other patients appeared to be of normal size, as has been found in most other travelers with this condition [7] . This "nonfinding" may differentiate this form of prostate infection from other etiologies of prostatitis. The findings of transrectal ultrasonography were also normal for all but 1 of our patients, who had an enlarged prostate. This finding is in contrast to the findings of Corachan et al. [7] , who observed either hyperechoic zones or calcification in all patients.
The cases presented in this report highlight the importance of searching for schistosomal eggs in semen specimens, because this can establish the final diagnosis. Thus, a request for sperm examination should be sent to a skilled parasotology laboratory, bearing in mind that this is not part of the routine workup either for suspected schistosomiasis or hematospermia. Although serological testing is not considered a good measure by which to distinguish between previous and current infection, in our particular study population (which can represent most travelers returning from an area of nonedemicity to an area of endemicity), it seemed satisfactory for this purpose because none of the patients previously had been exposed to freshwater in areas of endemicity. Because examination of semen may be difficult, serological testing may play an even more important role in the diagnosis of infection. The sensitivity and specificity of the FAST-ELISA and immunoblot assay performed at the CDC laboratory are 99% and 99%, respectively [10] . However, it should be noted that serological testing cannot be relied upon for evaluation of treatment failure or success, because the results of such testing remain positive for many years, even after treatment has been successful.
The recommended treatment for S. haematobium infection is praziquantel, 40 mg/kg given in 2 divided doses in a single day [12] . Three of the patients in our study received this treatment, and all had a clinical response within days; however, all 3 had experienced recurrence of infection after several months. The fourth patient, who received a higher dose as initial treatment, had no recurrence of his symptoms. It may be speculated that, for this particular complication, higher doses (given at the onset of infection) or a longer course of treatment is desirable. However, different schedules of praziquantel therapy for this infection do not exist. It is important to note that the patients in our study who had gross hematospermia may be patients with more-severe cases of infection. To address these points, multicenter studies of travelers returning to countries of nonendemicity should be performed. Although recent evidence suggests that resistance to praziquantel may be developing [13] , it is unlikely that such resistance was the cause of treatment failure in this study, because treatment failure was noted only among patients with hematospermia, not among patients with bladder schistosomiasis. Of interest, praziquantel is known to be parasiticidal against the adult worm of schistosome [14] ; however, in the cases cited, symptoms probably were due to the ectopic migration of eggs (although ectopic migration of the adult worms cannot be excluded). That all patients in this study did show a response to the drug within days after treatment initiation suggests that praziquantel has effects other than adult helminthicide. A similar observation has been made with regard to ectopic migration of eggs to the spinal cord [15] and early pulmonary schistosomiasis [16] . The incidence of cases of hematospermia among travelers is unknown. Corachan et al. [7] reported hematospermia in 10 of 29 male travelers to Mali. On the basis of findings for our entire cohort of travelers with schistosomiasis, we found 4 cases in 70 travelers, for an incidence of 5.7%. Thus, genital involvement seems to be more common than is generally perceived, especially in light of the self-reporting nature of this cohort.
In conclusion, genital involvement is not uncommon in cases of schistosomal infection. Coupled with the ever-increasing volume of worldwide travel, clinicians should consider schistosomiasis in the differential diagnosis of hematospermia. Making the correct diagnosis may be challenging and rewarding, although the best treatment has yet to be established.
